About our product, Mycosinate®
Nektr Technologies have completed its Phase II Comparator clinical trial against the European market leader with outstanding results.
Nektr’s breakthrough Technology, Mycosinate® has succeeded in outperforming the European market leader by over 5x in reducing infected area of the nail.
What is Onychomycosis?
Fungal Nail Infection or Onychomycosis is responsible for approximately 50% of all consultations for nail disorders globally. Onychomycosis has been reported as a gender and age-related disease, as it is more prevalent in males and its incidence increases with age. Its prevalence in the general population is estimated to be between 9%-and 14% in North America, and as high as 24% in Europe. Onychomycosis has also been found to be four times more prevalent in those over the age of 60 years. Risk factors contributing to increased incidence of fungal nail infection include diabetes mellitus, peripheral arterial disease or other circulatory issues, and a weakened immune system.
Fungal nail infections may cause nails to become discoloured, thick, fragile, or cracked. The nail may also become separated from the nail bed. Onychomycosis is more common in toenails than fingernails and can spread both to the rest of the nails of the same person, as well as to other people through surface contamination.
Figure 1: Difference between Treatment A (Mycosinate®) and Treatment B (5% Amorolfine) in percentage change in clear healthy nail area.
Figure 2: Mycosinate® average area of infection trends
Do you have questions about Nektr or our technology? Connect with us using the details below or get in touch by filling out the form We would be happy to answer your questions!
Finisklin Business & Technology Park,
Sligo, Ireland, F91 HF66